191 related articles for article (PubMed ID: 27002680)
1. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
Kavakli K; Yang R; Rusen L; Beckmann H; Tseneklidou-Stoeter D; Maas Enriquez M;
J Thromb Haemost; 2015 Mar; 13(3):360-9. PubMed ID: 25546368
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
Pickering W; Hansen M; Kjalke M; Ezban M
J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
[TBL] [Abstract][Full Text] [Related]
6. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
9. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
Oldenburg J; Windyga J; Hampton K; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Maas Enriquez M
Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
[TBL] [Abstract][Full Text] [Related]
12. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
13. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
[TBL] [Abstract][Full Text] [Related]
14. The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?
Schütte LM; Hodes LS; van Moort I; Stoof SCM; Leebeek FWG; Cnossen MH; de Maat MPM; Kruip MJHA
Haemophilia; 2020 Sep; 26(5):916-922. PubMed ID: 32713129
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.
Fujii T; Hanabusa H; Shima M; Morinaga T; Fukutake K
Int J Hematol; 2017 Mar; 105(3):280-286. PubMed ID: 27832514
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII.
Shah A; Delesen H; Garger S; Lalezari S
Haemophilia; 2015 Nov; 21(6):766-71. PubMed ID: 25952661
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
Yang R; Sun J; Zhao Y; Wang X; Wu D; Tseneklidou-Stoeter D; Wu J; Church N
Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
[TBL] [Abstract][Full Text] [Related]
18. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
Yan S; Maro GS; Desai V; Simpson ML
J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
[TBL] [Abstract][Full Text] [Related]
19. Considerations on activity assay discrepancies in factor VIII and factor IX products.
Ovanesov MV; Jackson JW; Golding B; Lee TK
J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
Church N; Leong L; Katterle Y; Ulbrich HF; Noerenberg I; Kitchen S; Michaels LA
Haemophilia; 2018 Sep; 24(5):823-832. PubMed ID: 29984531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
